NCT00760955已完成2 期
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy
Takeda0 个研究点目标入组 338 人开始时间: 2006年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 338
- 主要终点
- Change from Baseline for a composite measure of Maximal Nerve Conduction Velocity of the Peroneal and Median Motor Nerves and the Median and Sural Sensory Nerves.
研究概览
简要总结
The purpose of this study is to determine the safety and effectiveness of TAK-583, once daily (QD), in the treatment of neuropathy caused by diabetes mellitus.
详细描述
Diabetic polyneuropathy is a frequent complication in individuals with type 1 and 2 diabetes mellitus, and can result in progressive functional and structural deficits in both somatic and autonomic nerves. Diabetic polyneuropathy is characterized by degenerative changes in nerve fibers resulting in progressive functional and structural deficits in both somatic and autonomic nerves.
TAK-583 is a synthetic compound currently under development for the treatment of diabetic polyneuropathy. The purpose of this study is to evaluate the safety and efficacy of TAK-583 for the treatment of mild to moderate diabetic polyneuropathy in subjects with type 1 or type 2 diabetes mellitus. Study participation is anticipated to be about 8 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female subjects must be post-menopausal or status post documented hysterectomy and bilateral oophorectomy.
- •Has fasting clinical laboratory evaluations within the normal reference range for the testing laboratory, or if not, the results must be deemed not clinically significant by the investigator prior to randomization.
- •Has Type 1 or type 2 diabetes, as defined by World Health Organization Criteria.
- •Has mild to Moderate Diabetic Peripheral Neuropathy defined as:
- •Confirmed abnormality of at least two nerve conduction velocity parameters as defined by the Neurological Core Laboratory.
- •Sural sensory nerve potential amplitude greater than or equal to 1 μV (microvolt).
- •Has glycosylated hemoglobin less than or equal to 10%.
- •Is on stable pain medications for at least 3 weeks prior to randomization, if applicable.
- •Has a glomerular filtration rate calculated by Modification of Diet in Renal Disease of greater than or equal to 45 mL/min/ body surface area.
- •Spot albumin/creatinine ratio of less than 300 mg/g creatinine or 33.9 mg/mmol creatinine.
- •Has acceptable clinical laboratory test results as defined by:
- •Hemoglobin Greater than or equal to 9.0 g/dL or 5.58 mmol/L
- •Thyroid stimulating hormone Within normal limits
- •Free T4 index Within normal limits
- •B12 level Within normal limits
- •Is willing to follow an American Diabetes Association or similar recommended dietary regimen.
- •Exclusion Criteria
- •Individuals with a history of other neuropathies due to causes other than diabetes such as alcohol abuse, liver or renal disease, uremia, toxic exposure, genetic factors, autoimmune disorders, inflammatory demyelinating diseases, monoclonal gammopathies; or endocrine, metabolic or nutritional disorders.
- •Has clinical or electrophysiologic evidence of bilateral carpal tunnel syndrome.
- •Has a significant skin abnormality or ulcerative changes in their lower extremities that may interfere with the performance of the study related procedures.
- •Has a body mass index greater than 45 kg/m
- •Participants with uncontrolled hypertension or a systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure of greater than 95 mm Hg.
- •Has a history of myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, transient ischemic attacks, clinically significant abnormal electrocardiograms, New York Heart Association Functional Classification III or IV, or documented cerebrovascular accident.
- •Has a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval greater than 450 milliseconds).
- •Has a history of additional risk factors for Torsades de pointes.
- •Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- •Medications that prolong the QT/QTc interval.
- •Lipoic acid.
- •Linolenic acid (primrose oil).
- •Inositol.
- •Topiramate.
- •Acetyl-L-Carnitine.
- •Nerve growth factors.
- •Capsaicin.
- •CYP3A4 inhibitors (amiodarone, diltiazem, Verapamil)
- •HIV protease inhibitors
- •Itraconazole
- •Ketoconazole
- •macrolide antibiotics
- •CYP 3A4 inducers
- •Has an alanine aminotransferase level of greater than 1.5 times upper limit of normal, active liver disease or jaundice or Total bilirubin greater than 1.2 times upper limit of normal.
- •Has a 12-hour urinary cortisol test greater than 264 nmol/night (95.6 mcg/night) at screening.
- •Has clinically significant (as determined by the investigator) or unstable: pulmonary, gastrointestinal, hepatic, hematologic, musculoskeletal, osteoporosis, osteopenia, or endocrine (other than diabetes mellitus or stably treated hypothyroidism) diseases.
- •Has a previous history of cancer that has not been in remission for at least 5 years prior to the first dose of study drug.
- •Has any other serious disease or condition at screening or at randomization that might affect life expectancy or make it difficult to successfully manage and follow the subjects according to the protocol.
- •Has a history of drug abuse or a history of alcohol abuse within the past 2 years.
- •Has a known hypersensitivity to a compound related to TAK-
- •Is currently participating in another investigational study or has participated in an investigational study within the past 30 days.
排除标准
- 未提供
研究组 & 干预措施
TAK-583 5 mg QD
Experimental
干预措施: TAK-583 (Drug)
TAK-583 50 mg QD
Experimental
干预措施: TAK-583 (Drug)
TAK-583 100 mg QD
Experimental
干预措施: TAK-583 (Drug)
Placebo QD
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change from Baseline for a composite measure of Maximal Nerve Conduction Velocity of the Peroneal and Median Motor Nerves and the Median and Sural Sensory Nerves.
时间窗: Month 6 or Final Visit
次要结局
- Change from Baseline in Sensory Sub-Composite and Motor Sub-Composite Scores.(Months 3 and 6 or Final Visit)
- Change from Baseline in Electrophysiological Parameters for Individual Nerves.(Month 6 or Final Visit)
- Change in Neurological Examination Score.(Months 3 and 6 or Final Visit)
- Change in Quality of Life Index Score.(Months 1, 2, 3, 4, 5, and 6 or Final Visit)
- Change in glycosylated hemoglobin.(Months 3 and 6 or Final Visit)
- Change in fasting plasma glucose.(Months 3 and 6 or Final Visit)
- Change in Vibration Perception Threshold.(Months 3 and 6 or Final Visit)
- Change in Pain Scores.(Months 1, 2, 3, 4, 5, and 6 or Final Visit)
- Change in fasting insulin.(Months 3 and 6 or Final Visit)
- Change in Fasting C-peptide.(Months 3 and 6 or Final Visit)
研究者
相似试验
已完成
2 期
Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT01414920Takeda368
已完成
2 期
Efficacy and Safety of TAK-385 in the Treatment of EndometriosisEndometriosisNCT01458301Takeda487
已完成
2 期
Efficacy and Safety of TAK-385 in the Treatment of Uterine FibroidsUterine FibroidsNCT01452659Takeda216
已完成
2 期
Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral NeuropathyDiabetic NeuropathiesNCT00229437Takeda343
已完成
2 期
Efficacy and Safety of TAK-783 in Subjects With Rheumatoid ArthritisArthritis, RheumatoidNCT00760968Takeda224